DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for achondrogenesis type IA — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAchondrogenesis type IA maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for achondrogenesis type ia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Achondrogenesis type IA is a lethal skeletal dysplasia. The 1977 abstract describes it as a rare form of lethal dwarfism, usually discovered after birth, with only a few cases diagnosed in utero at that time. No drug or treatment is mentioned.
The 2017 review states that achondrogenesis type IA is associated with a mutation in the TRIP11 gene and appears to be autosomal recessive. Infants are usually born prematurely, are stillborn, or die shortly after birth from respiratory failure. No drug or intervention is discussed.
The 2019 case report describes a premature female infant whose clinical, radiological, and histopathological features were compatible with achondrogenesis type IA. The family had four affected products from six previous pregnancies. Statistical analysis of this family and at least four previously described families showed significant differences between expected and observed numbers of affected members, which the authors say is incongruent with the previously reported autosomal recessive inheritance. They propose this may represent a new subtype due to a preferential germline mutation. No treatment or drug is mentioned in any of the three abstracts.
No drug has been tested or proposed for achondrogenesis type IA in these abstracts. What is missing is any preclinical or clinical research into a therapeutic agent, any animal model work, any trial design, and any patient stratification beyond genetic subtyping.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren · 1977 · 10 citations
Achondrogenesis, Type I
AbstractAchondrogenesis ist eine seltene Art von tödlichem Zwergwuchs. Normalerweise wird sie nach der Geburt entdeckt; nur in einigen Fällen wurde sie im Uterus erkannt. Einer dieser Fälle wird hier zusammen mit der Differentialdiagnose von Achondrogenesis und den anderen Formen von tödlichem Zwergwuchs beschrieben. Zusammenfassung Achondrogenesis is a rare form of lethal dwarfism. Usually discovered post partum, in a few instances only it has been diagnosed in utero. One such a case is here presented together with differential diagnosis with other forms of lethal dwarfism.
International Journal of Reproduction Contraception Obstetrics and Gynecology · 2017 · 5 citations · open access
The genetic aspect and morphological appearance of achondrogenesis
AbstractAchondrogenesis (ACG) is a number of disorders that are the most severe form of congenital chondrodysplasia characterized with bones and cartilage malformation. Generally, characteristic of ACG is a small body, short limbs, and other skeletal abnormalities. As a result of infants with ACG their serious health problems, usually born prematurely, are stillborn, or die shortly after birth from respiratory failure. Currently 3 type variants of ACG such as ACG-1A, ACG-1B and ACG-2. ACG-1A appears to be autosomal recessive (AR), with thyroid hormone receptor interactor 11 (TRIP11) gen mutation, while ACG1B also appears to be AR, with diastrophic dysplasia sulfate transporter or DTDST (SLC26A2) gen mutation. ACG-2 is caused by autosomal dominant (AD), with type 2 collagen (COL2A1) gen mutation. ACG-1A had characterizid such as physis abnormal, vertebral bodies with unossified or smal and oval, skull poorly ossified, periodic acid–Schiff (PAS) stain positive chondrocyte inclusions finding in long bones. ACG-1B had physis abnormal, vertebral bodies with unossified or smal and oval, skull ossified, perichondrocyte collagen rings finding in long bones. ACG-2 also had physis abnormal, metaphyseal cupping, vertebral bodies with unossified or small and oval, enlarged chondrocyte lacunae.
Cirugía y Cirujanos (English Edition) · 2019 · 2 citations · open access
New subtype of familial achondrogenesis type IA (Houston-Harris)
AbstractBackground: Achondrogenesis is a skeletal dysplasia characterized primarily by short stature, severe micromelia, short and narrow chest, prematurity, polyhydramnios, fetal hydrops, and in utero or neonatal death. Based on the radiological and histopathological findings, there are three types of achondrogenesis: type 1A (Houston-Harris), type 1B (Fraccaro) and type 2 (Langer-Saldino). Clinical case: A premature female product was studied whose clinical, radiological and histopathological characteristics were compatible with achondrogenesis Type 1A. The family information allowed us to conclude that the 4 products of the 6 previous pregnancies were affected. Statistical analysis in at least 4 families previously described, including this family case showed significant differences between expected and observed number of members, being incongruent with an autosomal recessive mode of inheritance previously reported. Conclusions: therefore, it could be considered a new subtype of achondrogenesis type 1A due to the presence of a preferential germline mutation.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
